Quantification of Aerosol Hydrofluoroalkane HFA-134a Elimination in the Exhaled Human Breath Following Inhaled Corticosteroids Administration

Autor: Shin, HW, Barletta, B, Yoonessi, L, Meinardi, S, Leu, SY, Radom-Aizik, S, Randhawa, I, Nussbaum, E, Blake, DR, Cooper, DM
Rok vydání: 2015
Předmět:
Male
Hydrocarbons
Fluorinated
aerosol
bronchodilator
Chemistry
Pharmaceutical
gas chromatography
Vital Capacity
Cardiorespiratory Medicine and Haematology
California
Fluorinated
Adrenal Cortex Hormones
Original Research Articles
Forced Expiratory Volume
2-Tetrafluoroethane
Lung
General Clinical Medicine
Middle Aged
hydrofluoroalkane
Healthy Volunteers
Bronchodilator Agents
Chemistry
Breath Tests
Inhalation
Exhalation
Administration
Respiratory
Female
Drug Monitoring
Adult
Oncology and Carcinogenesis
Maximal Midexpiratory Flow Rate
compliance
Medication Adherence
Predictive Value of Tests
HFA-134a
Clinical Research
Administration
Inhalation
Humans
Albuterol
Aerosols
Other Medical and Health Sciences
asthma
Hydrocarbons
Aerosol Propellants
Pharmaceutical
Fluticasone
Albuterol inhaler
inhaled corticosteroids
propellant
Zdroj: Clinical and translational science, vol 8, iss 5
Shin, HW; Barletta, B; Yoonessi, L; Meinardi, S; Leu, SY; Radom-Aizik, S; et al.(2015). Quantification of Aerosol Hydrofluoroalkane HFA-134a Elimination in the Exhaled Human Breath Following Inhaled Corticosteroids Administration. Clinical and Translational Science. doi: 10.1111/cts.12305. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/8p4553j4
Shin, HW; Barletta, B; Yoonessi, L; Meinardi, S; Leu, SY; Radom-Aizik, S; et al.(2015). Quantification of Aerosol Hydrofluoroalkane HFA-134a Elimination in the Exhaled Human Breath Following Inhaled Corticosteroids Administration. Clinical and Translational Science, 8(5), 445-450. doi: 10.1111/cts.12305. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/3sk7r7s6
DOI: 10.1111/cts.12305.
Popis: © 2015 Wiley Periodicals, Inc. Inhaled corticosteroids (ICS) and β2-agonists are the primary pharmacotherapies of asthma management. However, suboptimal medication compliance is common in asthmatics and is associated with increased morbidity. We hypothesized that exhaled breath measurements of the aerosol used in the inhaled medications might prove useful as surrogate marker for asthma medication compliance. To explore this, 10 healthy controls were recruited and randomly assigned to ICS (Flovent HFA) or short acting bronchodilators (Proventil HFA). Both inhalers contain HFA-134a as aerosol propellant. Exhaled breath sampling and pulmonary function tests were performed prior to the inhaler medication dispersion, immediately after inhalation, then at 2, 4, 6, 8, 24, and 48 hours postadministration. At baseline, mean (SD) levels of HFA-134a in the breath were 252 (156) pptv. Immediately after inhalation, HFA-134a breath levels increased to 300 × 106 pptv and were still well above ambient levels 24 hours postadministration. The calculated ratio of forced expiratory volume in 1 second over forced vital capacity did not change over time following inhaler administration. This study demonstrates, for the first time, that breath HFA-134a levels can be used to assess inhaler medication compliance. It may also be used to evaluate how effectively the medicine is delivered.
Databáze: OpenAIRE
Externí odkaz: